Cited by — Ozoralizumab, a trivalent anti-TNFα NANOBODY® compound, is resistant to rheumatoid factor-mediated modulation of FcRn-dependent recycling and immune complex uptake | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite Ozoralizumab, a trivalent anti-TNFα NANOBODY® compound, is resistant to rheumatoid factor-mediated modulation of FcRn-dependent recycling and immune complex uptake.
No admitted local citation edges point to this work yet.
